Overview of Attending

CPHI India Delhi

26-28 Nov’2019
Executive Summery
CPHI unites more more than 100,000 Pharmaceuticals Professionals through
exhibition, conferences & online communities to network identify business
opportuities & expand the global markets.
CPHI India is the largest Fair/Platform of the south Asian reason. The objective of
the fair is exchanging of knowledge & Technical knowhow among the
pharmaceuticals professionals in globally.
As per instruction of the management of PPL following Departments are form to
attend CPHI India to develop new & alternative source management:
• Product Management Department
• Supply Chain Department
• Regulatory Department (New molecule sourcing)
Under the perspective of PMD
Under the perspective of RA

• To find out the suitable sources of our proposed new product which has been approved by USFDA, UK-MHRA or other regulatory agencies
very recently.
• Zoledronic Acid: We have received five (05) test sample which are INN specifications. But our specifications are BP as Zoledronic Acid is
included in BP pharmacopeia recently. We found a suitable source that is Hetero Drugs Ltd., India which comply with BP specifications and
they will provide us the test sample with WS within soonest.
• Semaglutide: We are facing difficulties to find suitable source with proper documentation. We arranged a meeting with Bachem AG,
Switzerland which all relevant required documents will be ready at the end of March’ 2020.
• Pegfilgrastim & Derbepoetin Alfa: These are Biosimilar products and our considerable pipeline products. Intas Biopharmaceuticals Ltd.,
India are agreed to supply us ready to fill (RTF) bulk with all regulatory documents including Clinical, Pre-clinical study reports.
• Valbenazine: We have arranged a meeting with Extrovis AG, Switzerland & Hetero Drugs Ltd., India for Valbenazine and they will send us
test sample with WS within this month. This product has already approved by DCC and proposal raised by PMD long before and listed as
top priority product but we didn’t get any source from local agent.
• Sotagliflozin, Lefamulin Acetate, Lasmiditan, Patiromer Sorbitex Calcium, Tenafanor HCL: These products are in our development
pipeline which has been approved by USFDA very recently. We have seated with different number of manufacturers for these products and
they agreed to support us with test sample and all required documents.
• Human Albumin 20%: This is our top priority product and we have planned to had meeting with them but unfortunately the manufacturer
itself couldn’t manage time at CPHI. But they will come Bangladesh for business collaboration meeting with us at January’ 2020.
Meanwhile, they have already share the COA and price quotation with us.
Conclusion:

• After successful development of these products, our current product portfolio will be highly enriched and ultimately increase our total sales
volume.
Under the perspective of Supply
Chin
To set the meeting with existing suppliers
Outcome of the meeting
• For Sulindac Issues: We have arrange a meeting with … the local representative of the company
is Relations Int. As the company manufacturing sulindac based on their own intermediate we
can get a significant price benefit of them, there is no chance to facing materials shortage. It is
mention that this company having al international regulatory certificates ( cGMP, WHO, FDA )
• Action Plan: Based on our specification they are supplied Development & PD sample ASAP
• Cefixime Issue: We have arrange a meeting with Director business development of Nectar life
science regarding Cefixime issues, if change our another approve source that is Nectar life
science we can get significant price benefit of them. It is mention that this source already using
renowned manufacturing company like Square, Beximco, Incepta, Healthcare & Reneta &
others.
• Action Plan: As per our approved souce we may procure as per management approval then we
can yearly ~ 1 crore savings.
For Bilastin
• We have arrange a meeting with our single approved source Lee
Pharma Ltd & as per our visit & Negotiation they are agree to reduce
30 USD/KG
• Action Plan: As per regular consumption it will be significant saving for
the company.
 Anatomy of Immediate Import & Benefit details

SL Item Name Yearly Current As per visit & Yearly Yearly

No Consumption Purchase Price Negotiation Saving IN Saving in
Kg/USD USD BDT
(Tentative) (Tentative)
01 Sulindac 10MT 256.5 240 165000 14190000

02 Bilastine 300kg 1300 1270 9000 774000

03 Cefixime (Micronized & 3.5MT 154 124 if we go 105000 9030000

Compacted) another approved
source Nectar Life
science
04 Amoxicilin Sodium Sterile 1.5MT 59 56 4500 387000

Total Savings Yearly 24381000